INS and Hypoglycemia: Safety endpoints included any adverse events, such as serious and severe adverse events, events probably and possibly related to insulin use, hypersensitivity, injection-site reactions, hypoglycemia (overall, combined clinically relevant and severe, and nocturnal), and weight gain.